Chlamydia and Ovarian Cancer Study
Author Information
Author(s): Roberta B. Ness, Caixia Shen, Debra Bass, Carlynn Jackson, Kristen Moysich, Robert Edwards, Robert C. Brunham
Primary Institution: University of Texas, Houston, TX, USA
Hypothesis
Does serologic evidence of Chlamydia trachomatis infection correlate with ovarian cancer risk?
Conclusion
The study found that women with ovarian cancer were less likely to have high levels of antibodies to Chlamydia trachomatis.
Supporting Evidence
- Women with ovarian cancer had lower odds of high chlamydia antibody titers.
- The study included 521 cases and 766 controls.
- Chlamydia serology was used as a marker for past pelvic inflammatory disease.
Takeaway
The study looked at women with and without ovarian cancer to see if those with higher chlamydia antibodies were more likely to have cancer, but it turned out they were less likely.
Methodology
The study was a population-based case-control study that tested women for chlamydia antibodies and compared those with ovarian cancer to controls.
Potential Biases
Potential bias due to the retrospective nature of PID reporting and the timing of blood collection.
Limitations
The study may have missed some women with prior PID due to the lack of sensitivity of serologic testing.
Participant Demographics
Women aged 25 and older, with a mix of ovarian cancer cases and population-based controls.
Statistical Information
P-Value
0.001
Confidence Interval
0.4–0.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website